Mays Cancer Center at UT Health SA

UT Health SA 梅斯癌症中心

基本信息

批准号：
10653938
负责人：
Andrew Jacob Brenner
金额：
$ 3.11万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-08-01 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10653938
关键词：
Acceleration Address Adult Agonist Antidepressive Agents Area Basic Science Bioinformatics Biology Biometry Bladder Urothelium Breast Cancer Center Cancer Etiology Cancer Survivor Catchment Area Child Childhood Malignant Brain Tumor Clinical Clinical Research Clinical Trials Collaborations Conduct Clinical Trials Dental Development Developmental Therapeutics Program Doctor of Medicine Doctor of Philosophy Drug Combinations Estrogen Receptor beta FDA approved Funding Glioblastoma Goals Grant Growth Health Hypoxia Immune response Immunologic Markers Immunooncology Immunotherapy Impaired cognition Institution Intervention Intervention Trial Investigational Drugs Investigational Therapies Journals Lead Libraries Malignant Neoplasms Malignant neoplasm of urinary bladder Mass Spectrum Analysis Medical MicroRNAs Modeling Mus Mutation NCI-Designated Cancer Center Natural Products Obesity associated cancer Patients Peer Review Peptides Pharmaceutical Chemistry Pharmaceutical Preparations Phase Physicians Physiological Play Preclinical Testing Prediction of Response to Therapy Prodrugs Prostate Publications RNA RNA methylation RNA-Binding Proteins Reporting Research Resource Sharing Role Schools Scientist Seminal Signal Pathway Sirolimus Strategic Planning T-Lymphocyte Testing Texas Therapeutic Therapeutic Agents Tissues Translational Research Universities Untranslated RNA Work aptamer austin cancer clinical trial cancer therapy clinical development drug development drug discovery drug repurposing early phase clinical trial genome-wide high throughput screening immunoregulation improved lead candidate malignant mouth neoplasm medulloblastoma member neuro-oncology new therapeutic target non-muscle invasive bladder cancer novel novel therapeutics programs safety testing small hairpin RNA small molecule structural biology targeted treatment therapeutic RNA therapeutic target therapy resistant translational pipeline translational potential translational scientist triple-negative invasive breast carcinoma tumor tumor immunology

项目摘要

Project Summary—Experimental and Developmental Therapeutics (EDT) Program The Experimental and Developmental Therapeutics (EDT) Program is one of three interactive research programs of the Mays Cancer Center (MCC) at the University of Texas Health San Antonio (UT Health SA). Andrew Brenner, M.D., Ph.D. and Manjeet Rao, Ph.D. serve as Co-Leaders of the EDT Program. The primary focus of the EDT Program is to improve treatment of cancer through basic, translational, and clinical research. The EDT Program is the hub for clinical development of discoveries made by all members of MCC. The EDT Program members have expertise spanning experimental and developmental therapeutics – from initial target discovery, to IND regulatory approval, to early-phase clinical trials. The EDT Program members pursue this research focused on three major themes: 1) Neuro-oncology; 2) Immuno-oncology; and 3) Drug repurposing. In addition to these major themes, the EDT Program has one emerging theme: Targeted therapeutics. EDT members will advance the translational potential within these themes through the following Specific Aims: 1) Discovery of novel targets; 2) Development of new therapeutic agents and approaches; and 3) Conduct of early-phase clinical trials of novel therapies. The EDT Program currently has 36 members, representing 13 departments within three schools (Medical, Dental and Graduate) at UT Health SA. Two members are from the University of Texas at Austin and one member from Texas State University. Fifteen members lead clinical trials. The EDT Program members have $5.7M of peer-reviewed cancer-related funding (27 grants). Of those, $2.7M are from 15 NCI grants. From January 2014 to June 2019, EDT Program members coauthored 414 peer-reviewed cancer-related publications, 24% were from intra-programmatic collaborations and 16% were from inter-programmatic collaborations. In addition, 79% of these publications involve multi-institutional collaborations, including 192 (46%) publications with other NCI-designated Cancer Centers. EDT members use all of the MCC-supported Shared Resources to pursue their cross-cutting research, especially the Biostatistics and Bioinformatics, Mass Spectrometry, Drug Discovery and Structural Biology facilities. EDT members have also led 130 interventional clinical trials, and in 2018 alone, 226 patients were accrued to intervention trials.

项目摘要 - 实验和发展治疗（EDT）计划实验和发展治疗学（EDT）计划是三个互动研究计划之一得克萨斯大学健康圣安东尼奥分校（UT Health SA）的梅斯癌症中心（MCC）安德鲁医学博士Brenner博士和Manjeet Rao博士担任EDT计划的共同领导者。主要重点 EDT计划是通过基本，翻译和临床研究来改善癌症的治疗。 EDT 计划是MCC所有成员发现发现的临床发展的枢纽。 EDT程序成员拥有跨越实验和开发治疗剂的专家 - 从最初的目标发现开始，进行IND监管批准，以进行早期临床试验。 EDT计划成员购买此研究专注于三个主要主题：1）神经肿瘤学； 2）免疫肿瘤学； 3）重新利用药物。此外对于这些主要主题，EDT计划具有一个新兴主题：有针对性的治疗。 EDT成员将通过以下特定目的提高这些主题中的翻译潜力：1）发现新目标； 2）开发新的治疗剂和方法； 3）早期临床的行为新疗法的试验。 EDT计划目前有36名成员，代表三个部门三个部门 UT Health SA的学校（医学，牙科和研究生）。两名成员来自德克萨斯大学的奥斯汀和一名来自德克萨斯州立大学的成员。 15名成员领导临床试验。 EDT程序会员有570万美元的同行评审癌症相关资金（27赠与）。其中，270万美元来自15 NCI 赠款。从2014年1月到2019年6月，EDT计划成员共同撰写了414次同行评审癌症相关的出版物，有24％来自截面的合作，有16％来自程序间合作协作。此外，这些出版物中有79％涉及多机构合作，包括192 （46％）与其他NCI指定的癌症中心的出版物。 EDT成员使用所有MCC支持的共享资源以进行横切研究，尤其是生物统计学和生物信息学，群众光谱，药物发现和结构生物学设施。 EDT成员还领导了130个介入临床试验，仅在2018年，就有226名患者接受干预试验。